801 Capitola Dr
Suite 104
Durham
NC
27713-4384
USA
919-313-2102
info@micell.com
Product Categories
Related Content
October 31, 2016 — Micell Technologies Inc. announced that it presented five-year clinical safety and efficacy results ...
October 31, 2016
February 17, 2015 — Micell Technologies, Inc. announced the commercial availability of the MiStent sirolimus-eluting ...
February 17, 2015
Nov. 14, 2014 — Micell Technologies Inc. announced commercialization plans for its MiStent Sirolimus Eluting Absorbable ...
November 14, 2014
Feature | Stents Bioresorbable| Dave Fornell
(UPDATE: read the Sept. 8, 2017 article "Abbott Will End Sales of Absorb Bioresorbable Stent") A key prediction for ...
September 03, 2014
July 15, 2014 — Micell Technologies Inc. announced the United States Patent and Trademark Office (USPTO) has issued a ...
July 15, 2014March 12, 2014 — Micell Technologies Inc. announced that imaging and clinical results from the DESSOLVE I and DESSOLVE ...
March 12, 2014October 8, 2013 — Micell Technologies Inc. announced that a peer reviewed article discussing imaging and clinical ...
October 08, 2013July 12, 2013 — Micell Technologies Inc. received CE mark approval for its MiStent sirolimus-eluting absorbable polymer ...
July 12, 2013
November 7, 2012 — Micell Technologies Inc. announced positive data from two clinical studies of its investigational ...
November 07, 2012
November 21, 2011 — Micell Technologies Inc. announced the release of preliminary data from the first-in-human clinical ...
November 21, 2011